Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

NCT02279173 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Eltrombopag for Refractory Thrombocytopenia Associated With Connective Tissue Disease

NCT06458803 ·Status: COMPLETED

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT02201290 ·Status: COMPLETED ·Phase: PHASE3

Eltrombopag Phase III Study In Chinese Chronic ITP Patients

NCT01762761 ·Status: COMPLETED ·Phase: PHASE3

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

NCT01071954 ·Status: COMPLETED ·Phase: PHASE3

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

NCT03664518 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

NCT02614846 ·Status: UNKNOWN ·Phase: PHASE1

Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)

NCT03771378 ·Status: UNKNOWN ·Phase: PHASE4

A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

NCT02403440 ·Status: UNKNOWN ·Phase: PHASE1

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

NCT04516967 ·Status: COMPLETED ·Phase: PHASE3

Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

NCT04917679 ·Status: COMPLETED ·Phase: PHASE2

Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)

NCT04949009 ·Status: UNKNOWN

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT01444417 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612 ·Status: COMPLETED ·Phase: PHASE2

Immune Markers in Pediatric ITP on Second Line Therapy

NCT06093529 ·Status: NOT_YET_RECRUITING

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

NCT06094881 ·Status: RECRUITING ·Phase: PHASE2

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

NCT03222843 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698 ·Status: COMPLETED ·Phase: PHASE2

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637 ·Status: COMPLETED ·Phase: PHASE3

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

NCT01610180 ·Status: COMPLETED ·Phase: PHASE2

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

NCT06168851 ·Status: RECRUITING ·Phase: PHASE2

Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura

NCT03830749 ·Status: COMPLETED ·Phase: PHASE2

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

NCT04638829 ·Status: COMPLETED ·Phase: PHASE4

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

NCT06107582 ·Status: RECRUITING